CN1446227B - 新型成纤维细胞生长因子(fgf23)及其使用方法 - Google Patents

新型成纤维细胞生长因子(fgf23)及其使用方法 Download PDF

Info

Publication number
CN1446227B
CN1446227B CN018140572A CN01814057A CN1446227B CN 1446227 B CN1446227 B CN 1446227B CN 018140572 A CN018140572 A CN 018140572A CN 01814057 A CN01814057 A CN 01814057A CN 1446227 B CN1446227 B CN 1446227B
Authority
CN
China
Prior art keywords
fgf23
nucleic acid
polypeptide
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN018140572A
Other languages
English (en)
Chinese (zh)
Other versions
CN1446227A (zh
Inventor
M·艾肯斯
K·怀特
T·M·斯特罗姆
T·梅廷格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEREDITY DEPARTMENT OF MEDICINE MUNICH-LUDWIG MAXIMILIANS UNIVERSITY
Advanced Research & Technology Inc
Original Assignee
HEREDITY DEPARTMENT OF MEDICINE MUNICH-LUDWIG MAXIMILIANS UNIVERSITY
Advanced Research & Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1446227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by HEREDITY DEPARTMENT OF MEDICINE MUNICH-LUDWIG MAXIMILIANS UNIVERSITY, Advanced Research & Technology Inc filed Critical HEREDITY DEPARTMENT OF MEDICINE MUNICH-LUDWIG MAXIMILIANS UNIVERSITY
Publication of CN1446227A publication Critical patent/CN1446227A/zh
Application granted granted Critical
Publication of CN1446227B publication Critical patent/CN1446227B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
CN018140572A 2000-07-19 2001-07-10 新型成纤维细胞生长因子(fgf23)及其使用方法 Expired - Lifetime CN1446227B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21913700P 2000-07-19 2000-07-19
US60/219,137 2000-07-19
PCT/US2001/021738 WO2002008271A1 (en) 2000-07-19 2001-07-10 Novel fibroblast growth factor (fgf23) and methods for use

Publications (2)

Publication Number Publication Date
CN1446227A CN1446227A (zh) 2003-10-01
CN1446227B true CN1446227B (zh) 2011-10-05

Family

ID=22818027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN018140572A Expired - Lifetime CN1446227B (zh) 2000-07-19 2001-07-10 新型成纤维细胞生长因子(fgf23)及其使用方法

Country Status (11)

Country Link
US (5) US7223563B2 (enExample)
EP (2) EP2184296A1 (enExample)
JP (2) JP2004504063A (enExample)
KR (2) KR20090036151A (enExample)
CN (1) CN1446227B (enExample)
AT (1) ATE461213T1 (enExample)
AU (2) AU7332301A (enExample)
CA (1) CA2418215A1 (enExample)
DE (1) DE60141582D1 (enExample)
ES (1) ES2340662T3 (enExample)
WO (1) WO2002008271A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108474008A (zh) * 2015-06-25 2018-08-31 阿迈瑞斯公司 麦芽糖依赖性降解决定子、麦芽糖响应型启动子、稳定化构建体及其在生成非分解代谢化合物中的用途
US11976303B2 (en) 2013-09-20 2024-05-07 Lonza Ltd Methods for nuclear reprogramming of cells

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
CN101275136A (zh) * 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
RU2003123108A (ru) * 2000-12-26 2005-02-27 Чугаи Сейяку Кабусики Кайся (Jp) Мутантные формы человеческого белка fgf23, снижающие содержание фосфора в крови
WO2002088358A2 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
DE60329070D1 (de) * 2001-12-28 2009-10-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen den fibroblastenwachstumsfaktor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
ATE507296T1 (de) * 2003-11-07 2011-05-15 Novartis Ag Verwendung von fibroblasten-wachstumsfaktor- fragmenten
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
EP1745151B1 (en) * 2004-05-09 2009-12-02 Technion Research And Development Foundation, Ltd. Methods relating to disorders associated with abnormal phosphate metabolism
MX2007013005A (es) * 2005-04-18 2008-01-16 Clearplay Inc Aparato, sistema y metodo para asociar uno o mas archivos de filtro con una presentacion multimedia particular.
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
US8012694B2 (en) 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
WO2008089936A1 (en) * 2007-01-22 2008-07-31 Medizinische Universität Innsbruck Novel markers for chronic kidney disease
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
US20110183434A1 (en) * 2008-01-17 2011-07-28 Myles Wolf Diagnostic methods and kits using fibroblast growth factor-23
US8420088B2 (en) * 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
EP3985393B1 (en) 2010-08-31 2023-10-04 Minaris Medical Co., Ltd. Method for measuring fibroblast growth factor-23 and reagent therefor
WO2012055096A1 (zh) * 2010-10-27 2012-05-03 温州医学院生物与天然药物开发中心有限公司 抗fgf-23抗体的制备方法及用途
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CN106456714A (zh) 2014-03-28 2017-02-22 纽约大学 Fgf23融合蛋白
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
DK3845245T3 (da) 2014-06-09 2025-09-15 Ultragenyx Pharmaceutical Inc Effektiv og virkningsfuld kontrol af serumphosphat til optimal knogledannelse
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA2969307A1 (en) 2014-12-04 2016-06-09 Novartis Ag Methods and compositions using klotho variant polypeptides
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3604503B1 (en) * 2017-03-28 2026-03-18 Ajinomoto Co., Inc. Additive for undifferentiation maintaining medium
US12498366B2 (en) 2017-05-31 2025-12-16 Canon Medical Diagnostics Corporation Measurement method for fibroblast growth factor-23 by forming immunocomplexes
WO2020047475A1 (en) * 2018-08-30 2020-03-05 The Uab Research Foundation Drug screening for fgf23-fgfr4 inhibitors
PH12021552414A1 (en) * 2019-03-29 2022-07-25 Atarga Llc Anti fgf23 antibody
EP3956354A1 (en) * 2019-04-19 2022-02-23 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
KR102987382B1 (ko) * 2020-11-27 2026-07-03 한국해양과학기술원 Fgf11 동형2 폴리펩타이드 및 그 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
JP2004522402A (ja) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
CA2391455A1 (en) * 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
EP1246843A1 (en) 2000-01-05 2002-10-09 ZymoGenetics, Inc. Novel fgf homolog zfgf12
EP1255771A4 (en) 2000-02-14 2004-09-29 Smithkline Beecham Corp NEW COMPOUNDS
CA2398603A1 (en) * 2000-02-15 2001-08-23 Amgen, Inc. Fibroblast growth factor-23 molecules and uses thereof
WO2001066595A2 (en) * 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002076467A1 (en) * 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
White et al..Autosomal dominant hypophosphataemic rickets is associatedwith mutations in FGF23.Nature Genetics26.2000,345-348. *
Yamashita et. al..Identificationo f a novel fibroblast growth factor,FGF-23,preferentially expressed in the ventrolateral thalamic nucleusof the brain.Biochemical and biophysical research communications277 2.2000,494-498.
Yamashita et. al..Identificationo f a novel fibroblast growth factor,FGF-23,preferentially expressed in the ventrolateral thalamic nucleusof the brain.Biochemical and biophysical research communications277 2.2000,494-498. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976303B2 (en) 2013-09-20 2024-05-07 Lonza Ltd Methods for nuclear reprogramming of cells
CN108474008A (zh) * 2015-06-25 2018-08-31 阿迈瑞斯公司 麦芽糖依赖性降解决定子、麦芽糖响应型启动子、稳定化构建体及其在生成非分解代谢化合物中的用途
CN108474008B (zh) * 2015-06-25 2026-06-12 阿迈瑞斯公司 麦芽糖依赖性降解决定子、麦芽糖响应型启动子、稳定化构建体及其在生成非分解代谢化合物中的用途

Also Published As

Publication number Publication date
CN1446227A (zh) 2003-10-01
US8586317B2 (en) 2013-11-19
US7745406B2 (en) 2010-06-29
US20020156001A1 (en) 2002-10-24
EP1303536A4 (en) 2005-01-05
US20080241946A1 (en) 2008-10-02
DE60141582D1 (de) 2010-04-29
AU7332301A (en) 2002-02-05
WO2002008271A1 (en) 2002-01-31
US20090311792A1 (en) 2009-12-17
US20120064544A1 (en) 2012-03-15
KR20030029111A (ko) 2003-04-11
EP1303536B1 (en) 2010-03-17
ATE461213T1 (de) 2010-04-15
JP2008194039A (ja) 2008-08-28
EP2184296A1 (en) 2010-05-12
AU2001273323B2 (en) 2005-11-10
US7314618B2 (en) 2008-01-01
CA2418215A1 (en) 2002-01-31
EP1303536A1 (en) 2003-04-23
US7947810B2 (en) 2011-05-24
JP2004504063A (ja) 2004-02-12
US20030181379A1 (en) 2003-09-25
KR100924183B1 (ko) 2009-10-28
US7223563B2 (en) 2007-05-29
ES2340662T3 (es) 2010-06-08
KR20090036151A (ko) 2009-04-13

Similar Documents

Publication Publication Date Title
US7947810B2 (en) Kits for diagnosing a hypophosphatemic disorder
AU2001273323A1 (en) Novel fibroblast growth factor (FGF23) and methods for use
US7063958B1 (en) Nucleic acids db, the receptor for leptin
PT2045322E (pt) Musculatura dupla em mamíferos
WO1997026335A9 (en) Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
KR20010023325A (ko) 함지방세포-특이적 단백질 상동체
US20050059120A1 (en) Compositions, methods, and kits relating to resistin-like molecules
WO2004083381A2 (en) Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
US6590089B1 (en) RVP-1 variant differentially expressed in Crohn's disease
US20050049212A1 (en) Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
US20030054446A1 (en) Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
CA2251603A1 (en) Gene family associated with neurosensory defects
AU2476301A (en) DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7084252B1 (en) DB, the receptor for leptin
US20030125296A1 (en) Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
WO2002055551A1 (fr) Nouveaux polypeptides, antigene 56.87 humain cd63, et polynucleotide codant ce polypeptide
CN1351081A (zh) 具有抑制癌细胞生长功能的新的人蛋白及其编码序列
US20020132238A1 (en) Progesterone receptor complex p23-like protein
NZ507864A (en) DADD, death activator death domain protein
JP2003000246A (ja) 松果腺特異的遺伝子−１
JPH11266870A (ja) 新規タンパク質およびそのｄｎａ
JP2004507242A (ja) 腎臓特異タンパク質
WO2001040289A1 (fr) Nouveau polypeptide, support mitochondrial 12, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20111005